Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Roche’s Chugai unit and AstraZeneca’s Alexion have settled a years long patent battle over the latter’s Ultomiris — a rare blood disorder treatment designed to succeed Alexion’s blockbuster Soliris, according to reports.